T. Mekori
About
In The Last Decade
T. Mekori
35 papers receiving 266 citations
Peers
Comparison fields: 5 of 69
- Oncology 136
- Immunology 131
- Molecular Biology 51
- Radiology, Nuclear Medicine and Imaging 45
- Surgery 44
Countries citing papers authored by T. Mekori
This map shows the geographic impact of T. Mekori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Mekori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Mekori more than expected).
Fields of papers citing papers by T. Mekori
This network shows the impact of papers produced by T. Mekori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Mekori. The network helps show where T. Mekori may publish in the future.
Co-authorship network of co-authors of T. Mekori
This figure shows the co-authorship network connecting the top 25 collaborators of T. Mekori. A scholar is included among the top collaborators of T. Mekori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Mekori. T. Mekori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 7 | |
| 2 | 16 | |
| 3 | 30 | |
| 4 | The effect of in vitro irradiation on human NK cell activity. A preliminary report. | 6 |
| 5 | 5 | |
| 6 | 10 | |
| 7 | Prostaglandin-related and adherent cell suppressor system in apparently cured Hodgkin's disease patients. | 3 |
| 8 | 1 | |
| 9 | 1 | |
| 10 | 11 | |
| 11 | 4 | |
| 12 | 3 | |
| 13 | 3 | |
| 14 | Adjuvant therapy in colorectal cancer. (A randomized trial comparing radio-chemotherapy and radio-chemotherapy combined with the methanol extraction residue of BCG, MER). | 7 |
| 15 | 4 | |
| 16 | 6 | |
| 17 | 14 | |
| 18 | Immunotherapeutic studies in mice with the methanol-extraction residue (mer) fraction of BCG: solid tumors. | 23 |
| 19 | Antibody production by 'cloned' cell populations. | 6 |
| 20 | 20 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.